Targovax reports Phase I data for ONCOS-102 in melanoma

Targovax A/S (OSE:TRVX) reported data from four evaluable patients with advanced or unresectable melanoma who progressed despite prior treatment with a checkpoint inhibitor in the Phase I ONCOS C824 trial showing that ONCOS-102 plus anti-PD-1 mAb Keytruda pembrolizumab induced immune activation at three weeks as measured by increased pro-inflammatory cytokines, cytotoxic CD8+ T cells and PD-1 expression on CD8+ T cells.

Patients received three doses of 3x10¹¹ viral particles intratumoral ONCOS-102 on days one, four and eight preceded by cyclophosphamide for three days prior to the first ONCOS-102 dose. Patients then received Keytruda at week three and every three weeks for up to 24 weeks...